NEW YORK, Sept. 25 — Daiichi Fine Chemical Co., Ltd. of
Japan today announced that it has selected world-renowned Cardiologist Dr.
John A. Rumberger and the Contract Research Division of KGK Synergize Inc.
to launch a new clinical trial to investigate the effect of Pantethine as a
dietary supplement for lipid management and the reduction of cardiovascular
risk factors in the North American population.
The randomized, double-blind placebo controlled study will be conducted
in two North American locations by Ontario-based KGK under the direction of
Dr. Dale Wilson, KGK medical director and principal investigator for the
An internationally recognized specialist in preventive cardiology,
Rumberger currently is director of cardiac imaging at the Princeton (N.J.)
Longevity Center, clinical professor of medicine at Ohio State University
and former professor of medicine at the Mayo Clinic. He also is author of
‘The Way Diet’ which provides information about optimal diet,
supplementation, exercise and stress management in preventing heart
disease. He will offer consultation on protocol design and comment on the
findings of the clinical trial.
The study design process started last month, study subjects at low to
moderate risk levels of cardiovascular disease will be treated over a
16-week period, and results are expected by the third quarter of 2009.
Daiichi Fine Chemical, sponsor of the study, is the world’s leading
supplier of pantothenic acid (vitamin B5) and its derivatives, including
pantethine, marketed under the brand name Pantesin(R). Sold in Japan for
more than 35 years, Pantesin has been available as a dietary supplement in
the United States since 1992. Although Pantesin’s effectiveness in safely
lowering cholesterol levels has been documented in more than 30 clinical
studies, the new study will be the most expansive ever conducted using
North American subjects.
“Maintaining an optimal balance among LDL, HDL, and triglycerides is
more important than simply lowering cholesterol and key to cardiovascular
health,” Rumberger said. “A low-fat and modified carbohydrate diet,
exercise and regular consumption of dietary supplements formulated with
scientifically proven, high quality ingredients can help individuals
achieve a healthy blood lipid profile.
“A large body of research points to Pantethine’s effectiveness in Asian
and Western European populations, where oral administration of Pantethine
has consistently shown an ability to favorably impact a variety of risk
factors in people with hypercholesterolemia, arteriosclerosis and diabetes.
The aim of the current trial is to confirm these results in a clinical
setting in North America where cardiovascular disease is the leading cause
Founded in 1997 by three scientists associated with the Centre for
Human Nutrition at The University of Western Ontario, KGK maintains a
global reputation for uncompromising science focused on nutraceutical,
biotechnology and pharmaceutical product research.
“Our team of research experts is devoted to discovering the unique
properties inherent in natural products that enhance and promote a healthy
lifestyle,” said KGK President and Chief Executive Officer Najla Guthrie.
“Our in-house lab and clinic along with our location at a leading
scientific and medical research center ensure timely and conclusive
research results overseen by leading physicians in the area of study.”
Daiichi Fine Chemical is a global leader in researching the use of
pantethine. By commissioning this new clinical trial, Daiichi signals its
continued support of research that takes into account lifestyle changes and
breakthrough discoveries that may impact the role Pantethine can play in
enhancing cardiovascular health.
About Daiichi Fine Chemical
Daiichi Fine Chemical Co. Ltd., is the world’s largest supplier of the
cholesterol-management agent pantethine, a derivative of vitamin B5, which
it markets under the brand name Pantesin(R). Daiichi Fine Chemical has a
reputation of strict pharmaceutical GMP standards at the firm’s vertically
integrated operation in Japan which are applied to Pantesin(R). Kyowa Hakko
Kogyo Co., Ltd., Japan acquired all shares of Daiichi Fine Chemical from
Daiichi-Sankyo Co., Ltd. in 2007. As a wholly owned subsidiary in Kyowa’s
bio-chemical business, Daiichi Fine Chemical continues to supply vitamin B5
of highest quality standards. For more information visit
About KGK Synergize, Inc.
Created in 1997 by three experienced nutritional scientists from
University of Western Ontario to facilitate commercialization of research
and development findings, KGK Synergize, Inc. provides contract research
services to health nutrition, biotechnology and pharmaceutical industries.
In addition to providing contract research services, KGK’s Product
Development Division brings new and innovative natural health products to
the point where they are ready to be manufactured and marketed. For more
information visit http://www.kgksynergize.com
SOURCE Daiichi Fine Chemical Co., Ltd. of Japan